ALYREF and lung cancer: Liu et al. have constructed a risk model by using 5 m5C RNA regulators, including ALYREF, to classify patients with lung cancer into high-risk (poorer OS) and low-risk (better response to immune checkpoint blockade therapy) groups [26].